Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Menactra®, DAPTACEL®, IPOL
Polysaccharide Diphtheria Toxoid Conjugate Vaccine · 1 trial · 5 indications
Serum antibody titers were assessed for diphtheria by a seroneutralization assay and for tetanus by enzyme linked immunosorbent assay.
Serum antibody titers against meningococcal serogroups A, C, Y, and W-135 were assessed by serum bactericidal assay using human complement (SBA HC)
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | DAPTACEL® + IPOL on Day 0 and Menactra on Day 30 |
| Group 2 | EXPERIMENTAL | DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30 |
| Group 3 | EXPERIMENTAL | Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30 |
| Name | Type | Description |
|---|---|---|
| Polysaccharide Diphtheria Toxoid Conjugate Vaccine | BIOLOGICAL | 0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30) |
Inclusion Criteria: * Healthy, as determined by medical history and physical examination. * Aged 4 to \< 7 years at the time of study vaccination on Day 0. * Informed consent form that has been approved by the Institutional Review Board (IRB) and signed/dated by the parent or legal guardian. * Prev...
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is used for the prevention of meningococcal meningitis. It is a vaccine developed by Sanofi. The vaccine is designed to protect against meningococcal disease, which can cause meningitis. It is given to children and adults to prevent infection.
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is made by Sanofi, which trades under the ticker symbol SNY. Sanofi is a global pharmaceutical company that develops and manufactures vaccines and other medicines. The vaccine is part of Sanofi's portfolio of infectious disease products.
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 2 trial has been completed, and further studies may be needed to support potential approval.
Polysaccharide Diphtheria Toxoid Conjugate Vaccine has been studied in a completed Phase 2 clinical trial, NCT00355121. The trial enrolled 882 children aged 4 to 6 years in the United States and evaluated the vaccine when given with a fifth dose of DAPTACEL. The trial was randomized, double-blind, and controlled.
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is also known as Menactra. Menactra is a vaccine used to prevent meningococcal meningitis. It is developed by Sanofi and has been studied in clinical trials for use in children and adults.